Becton, Dickinson and Company (BD) has reported a 26.9% growth in revenues on a reported basis to $4.9bn in the third fiscal quarter (Q3) ended 30 June 2021, compared with $3.9bn in the same quarter last year.

The revenues grew 22% on a currency-neutral basis for the quarter.

BD attributed the rise in revenue to robust base business performance owing to continued improvement of overall healthcare usage levels from the early Covid-19 impact.

For the quarter, GAAP diluted earnings per share (EPS) increased by 77.3% to $1.72 compared with $0.97 in the year-ago quarter.

BD recorded a growth of 24.5% on a reported basis or 25.9% on a currency-neutral basis in the adjusted diluted EPS to $2.74 in Q3 of this fiscal year (FY) compared to $2.20 in the same period last year.

The Q3 FY2021 revenues in the BD Medical segment reached $2.4bn from $2.12bn in the year-ago quarter, witnessing an 11.9% increase on a reported basis and a 7.7% growth on a currency-neutral basis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the quarter, BD Life Sciences revenues rose to $1.4bn from $951m, marking a 50.7% increase on a reported basis and 43.4% on a currency-neutral basis.

Revenue growth of BD Integrated Diagnostic Solutions (IDS) comprised $300m in sales linked to Covid-19 diagnostic testing on the BD Veritor Plus and BD Max Systems as against $98m last year.

BD noted that the Veritor Plus System alone generated revenues of $212m.

Furthermore, revenues in BD Interventional segment for Q3 was $1.1bn, a rise of 38.4% on a reported basis and 34.6% on a currency-neutral basis, compared to $782m in the third fiscal quarter of 2020.

Revenues in the US were $2.6bn in Q3 FY2021 against $2.12bn in the same quarter last year, signifying a growth of 21.5%.

Outside of the US, revenues rose to $2.32bn, representing a 33.5% surge on a reported basis and 22.6% on a currency-neutral basis.

BD chairman, CEO and president Tom Polen said: “Our strong third-quarter results reflect continued momentum across our base business.

“Solid execution by our teams has strengthened our foundation while increased investment in R&D and tuck-in M&A are enhancing our innovation pipeline.”

The company has updated its outlook for FY2021 and expects the revenues to increase by nearly 16.5% to 17.0% on a reported basis from the earlier guidance of 12% to 14%.

In addition, the company updated the adjusted diluted EPS for the year to $12.85 to $12.95 from $12.75 to $12.85.

BD reported revenues of $4.9bn in the second fiscal quarter ended 31 March, representing an increase of 15.4% on a reported basis, compared with $4.25bn in the same period last year.